These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15148495)

  • 1. Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support.
    Nieto Y; Franklin WA; Jones RB; Berman SI; Pellom J; Barón AE; Shpall EJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):415-25. PubMed ID: 15148495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: predictors and clinical relevance.
    Pecora AL; Lazarus HM; Jennis AA; Preti RA; Goldberg SL; Rowley SD; Cantwell S; Cooper BW; Copelan EA; Herzig RH; Meagher R; Kennedy MJ; Akard LR; Jansen J; Ross A; Prilutskaya M; Glassco J; Kahn D; Moss TJ
    Biol Blood Marrow Transplant; 2002; 8(10):536-43. PubMed ID: 12434948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.
    Nieto Y; Cagnoni PJ; Shpall EJ; Xu X; Murphy J; Vredenburgh J; Chao NJ; Bearman SI; Jones RB
    Clin Cancer Res; 1999 Nov; 5(11):3425-31. PubMed ID: 10589754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT).
    Syme R; Stewart D; Rodriguez-Galvez M; Luider J; Auer Y; Klassen J; Morris D; Brown C; Russell J; Glück S
    Bone Marrow Transplant; 2003 Aug; 32(3):307-11. PubMed ID: 12858203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation.
    Solano C; Badia B; Lluch A; Marugan I; Benet I; Arbona C; Prosper F; García-Conde J
    Bone Marrow Transplant; 2001 Feb; 27(3):287-93. PubMed ID: 11277176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy.
    Schneeweiss A; Goerner R; Hensel MA; Lauschner I; Sinn P; Kaul S; Egerer G; Beldermann F; Geberth M; Solomayer E; Grischke EM; Haas R; Ho AD; Bastert G
    Biol Blood Marrow Transplant; 2001; 7(6):332-42. PubMed ID: 11464976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation.
    Nieto Y; Cagnoni PJ; Nawaz S; Shpall EJ; Yerushalmi R; Cook B; Russell P; McDermit J; Murphy J; Bearman SI; Jones RB
    J Clin Oncol; 2000 May; 18(10):2070-80. PubMed ID: 10811672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant.
    Nieto Y; Shpall EJ; McNiece IK; Nawaz S; Beaudet J; Rosinski S; Pellom J; Slat-Vasquez V; McSweeney PA; Bearman SI; Murphy J; Jones RB
    Clin Cancer Res; 2004 Aug; 10(15):5076-86. PubMed ID: 15297410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors.
    Gerber B; Krause A; Müller H; Richter D; Reimer T; Makovitzky J; Herrnring C; Jeschke U; Kundt G; Friese K
    J Clin Oncol; 2001 Feb; 19(4):960-71. PubMed ID: 11181658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy.
    Schneeweiss A; Diel I; Hensel M; Kaul S; Sinn HP; Unnebrink K; Rudlowski C; Lauschner I; Schuetz F; Egerer G; Haas R; Ho AD; Bastert G
    Ann Oncol; 2004 Nov; 15(11):1627-32. PubMed ID: 15520063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
    Vredenburgh JJ; Silva O; Broadwater G; Berry D; DeSombre K; Tyer C; Petros WP; Peters WP; Bast RC
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):91-7. PubMed ID: 9267669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy.
    Viret F; Chabannon C; Sainty D; Genre D; Gonçalves A; Arnoulet C; Gravis G; Bertucci F; Houvenaeghel G; Jacquemier J; Bardou VJ; Ladaique P; Braud AC; Maraninchi D; Viens P
    Bone Marrow Transplant; 2003 Dec; 32(11):1059-64. PubMed ID: 14625576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Status of high-dose chemotherapy for breast cancer: a review.
    Nieto Y; Champlin RE; Wingard JR; Vredenburgh JF; Elias AD; Richardson P; Glaspy J; Jones RB; Stiff PJ; Bearman SI; Cagnoni PJ; McSweeney PA; LeMaistre CF; Pecora AL; Shpall EF
    Biol Blood Marrow Transplant; 2000; 6(5):476-95. PubMed ID: 11063377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation.
    Boudin L; Chabannon C; Sfumato P; Sabatier R; Bertucci F; Tarpin C; Provansal M; Houvenaeghel G; Lambaudie E; Tallet A; Resbeut M; Charafe-Jauffret E; Calmels B; Lemarie C; Boher JM; Extra JM; Viens P; Gonçalves A
    Eur J Cancer; 2016 Apr; 57():118-26. PubMed ID: 26918737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support.
    Hensel M; Schneeweiss A; Sinn HP; Egerer G; Solomayer E; Haas R; Bastert G; Ho AD
    Int J Cancer; 2002 Jul; 100(3):290-6. PubMed ID: 12115543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer.
    Nieto Y; Vredenburgh JJ; Shpall EJ; Bearman SI; McSweeney PA; Chao N; Rizzieri D; Gasparetto C; Matthes S; Barón AE; Jones RB
    Clin Cancer Res; 2004 Nov; 10(21):7136-43. PubMed ID: 15534084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support.
    Hensel M; Schneeweiss A; Sinn HP; Egerer G; Kornacker M; Solomayer E; Haas R; Bastert G; Ho AD
    Stem Cells; 2002; 20(1):32-40. PubMed ID: 11796920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support.
    Bewick M; Chadderton T; Conlon M; Lafrenie R; Morris D; Stewart D; Glück S
    Bone Marrow Transplant; 1999 Aug; 24(4):377-84. PubMed ID: 10467326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer.
    Rowlings PA; Williams SF; Antman KH; Fields KK; Fay JW; Reed E; Pelz CJ; Klein JP; Sobocinski KA; Kennedy MJ; Freytes CO; McCarthy PL; Herzig RH; Stadtmauer EA; Lazarus HM; Pecora AL; Bitran JD; Wolff SN; Gale RP; Armitage JO; Vaughan WP; Spitzer G; Horowitz MM
    JAMA; 1999 Oct; 282(14):1335-43. PubMed ID: 10527180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic importance of the axillary lymph node ratio in autologous transplantation for high-risk stage II/III breast cancer.
    Bolwell B; Andresen S; Pohlman B; Sobecks R; Goormastic M; Rybicki L; Bell K; Kalaycio M
    Bone Marrow Transplant; 2001 Apr; 27(8):843-6. PubMed ID: 11477442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.